GSK plc (GSK)

NYSE: GSK · Pharmaceutical Preparations · London · filing with the SEC since 2001

Full chart Alerts Compare

Grade6.2

◀ Past 7.2● Present 6.4▶ Future 4.9

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of GSK plc

Nine metrics read from its own filings, by tense

Headline grade

6.2/10

◀ Past7.230% of the headline

● Present6.440% of the headline

▶ Future4.930% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

7.2/1030% of the headline grade · 3 of 3 filed

Surviving crises

as filed

8.2/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 33% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

GSK plc's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

6.9/10

What has it actually done, year after year?

+1.8% a year over 10 filed years; profitable in 10 of 10.

weight 45% of this tense · 69th percentile among 323 sector filers · read for its customers

From the record

GSK plc's 10 filed years say what it did: revenue went from GBP 28 billion in fiscal 2016 to GBP 33 billion in fiscal 2025, up 1.8% a year; it rose in 8 of 9 years; the deepest fall was 28% from fiscal 2019 to fiscal 2020; net income was positive in 10 of 10 of those years (its annual reports).

What it rests on

revenue growth over the filed span1.8%bottom 31% of its family
the share of years revenue rosetop 18% of its family
the share of filed years with a profittop 3% of its family
the deepest fall from a revenue peak27.8%top 35% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

as filed

6.5/10

How has it treated the people who own it?

Share count grew 0.3% a year. 7% of cash flow returned. Insiders: 0 sales, 0 purchases.

weight 22% of this tense · 65th percentile among 80 sector filers · read for its shareholders

From the record

Over the 3 fiscal years to 2025-12-31, GSK plc's diluted share count grew about 0.3% a year, and dividends and buybacks returned about 7% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

What it rests on

the share count over the yearstop 12% of its family
cash returned against operating cash flowbottom 43% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

● Present

What are they doing right now?

6.4/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

7.0/10

Is it financially healthy right now?

ROE 39%: 39¢ of profit per shareholder dollar. Leverage 74%: owes 74¢ per asset dollar.

weight 45% of this tense · 70th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, GSK plc earned about 39 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 39 cents per dollar of everything the company owns. Leverage: it owed about 74 cents per dollar of assets, and net share issuance: its share count shrank 0.6% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 20% of its family
return on equitytop 3% of its family
gross profit against assetstop 30% of its family
the share count against the year beforetop 6% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

6.7/10

How strong is its position in its industry?

top 33% of 315 in its family; net margin 19.3%.

weight 33% of this tense · 67th percentile among 315 sector filers · read for its customers

From the record

GSK plc's standing among 315 graded names in its industry family: revenue of GBP 33 billion in fiscal 2025 is not ranked by size, since the family reports in another currency; a net margin of 19.3% ranks in the top 11%; revenue growth of 3.7% a year over the last 3 filed years ranks in the bottom 44% (its annual reports).

What it rests on

net margin19.3%top 11% of its family
three-year revenue growth3.7%bottom 44% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read.
How it was reasoned: family median, 371 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: GSK plc's leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

4.9/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

4.4/10

How much room does it have to grow?

bottom 44% of 273 in its family for room to expand.

weight 45% of this tense · 44th percentile among 273 sector filers · read for itself

From the record

GSK plc's room to grow, from the newest filed statements (fiscal 2025): cash of GBP 3.4 billion against debt of GBP 14 billion leaves -18.1% of its assets as net cash, bottom 8% of its family; cash from operations less capital spending is 19.6% of revenue (top 13%); a gross margin of 72.4% (top 48%); research spending of 23% of revenue (bottom 29%) (its annual report).

What it rests on

cash less debt against assets-18.1%bottom 8% of its family
cash from operations less capital spending against revenue19.6%top 13% of its family
gross margin72.4%top 48% of its family
research spending against revenue23.0%bottom 29% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

6.2/10

What could actually drive growth from here?

top 38% of 306 in its family for growth drivers.

weight 33% of this tense · 62nd percentile among 306 sector filers · read for its customers

From the record

GSK plc's growth drivers, from the filed years to fiscal 2025: revenue grew 3.7% a year over the last three filed years against 1.8% over all 10, speeding up (top 26% of its family); the newest year grew 4.1% (bottom 44%); research spending grew 11.1% a year (top 37%); capital spending grew 5.7% a year (top 33%) (its annual reports). GSK plc tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+1.9 points a yeartop 26% of its family
the newest year's revenue growth4.1%bottom 44% of its family
three-year growth of research spending11.1%top 37% of its family
three-year growth of capital spending5.7%top 33% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

4.0/10

Did its newest year beat what its own record pointed to?

bottom 40% of 233 in its family for expectations against reality.

weight 22% of this tense · 40th percentile among 233 sector filers · read for its shareholders

From the record

GSK plc's newest year against its own record: revenue of GBP 33 billion in fiscal 2025 came in 0.7% above the GBP 32 billion its prior three years' pace pointed to (top 43% of its family); net income of GBP 6.3 billion against a prior three-year average of GBP 8.0 billion (bottom 33%); a net margin of 19.3% against 26.7% before (bottom 30%) (its annual reports).

What it rests on

revenue against the prior three years' pace0.7%top 43% of its family
net income against the prior three years' average-21%bottom 33% of its family
net margin against its prior average-7.5 pointsbottom 30% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton GSK · research, not advice